Pharmanutra S.p.A.

Milan Stock Exchange PHN.MI

Pharmanutra S.p.A. Price to Sales Ratio (P/S) on January 14, 2025: 4.65

Pharmanutra S.p.A. Price to Sales Ratio (P/S) is 4.65 on January 14, 2025, a -17.88% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Pharmanutra S.p.A. 52-week high Price to Sales Ratio (P/S) is 5.87 on February 14, 2024, which is 26.11% above the current Price to Sales Ratio (P/S).
Pharmanutra S.p.A. 52-week low Price to Sales Ratio (P/S) is 4.25 on June 11, 2024, which is -8.65% below the current Price to Sales Ratio (P/S).
Pharmanutra S.p.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 5.05.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Milan Stock Exchange: PHN.MI

Pharmanutra S.p.A.

CEO	Mr. Andrea Lacorte
IPO Date	July 18, 2017
Location	Italy
Headquarters	Via delle Lenze 216/B
Employees	112
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

Key trends

Past 5 years